Tumor necrosis factor alpha (TNFα) is a complicated cytokine which is involved in proliferation and differentiation of acute myelogenous leukemia (AML) cells through a poorly understood mechanism. Mechanistic studies indicate that TNFα induced binding of PI3K subunit p85α to N-terminal truncated nuclear receptor RXRα (tRXRα) proteins, and activated AKT. The activated PI3K/AKT pathway negatively regulated differentiation of AML cells through the upregulation of c-Myc. In addition, TNFα also induced activation of nuclear factor κB (NF-κB), a nuclear transcription factor which was shown to promote cell proliferation. The present study demonstrates that oroxylin A, a natural compound isolated from Scutellariae radix, sensitizes leukemia cells to TNFα and markedly enhances TNFα-induced growth inhibition and differentiation of AML cell including human leukemia cell lines and primary AML cells. Activation of PI3K/AKT pathway could be inhibited by oroxylin A through inhibiting expression of tRXRα in NB4 and HL-60-resistant cells. Furthermore, we found that oroxylin A inhibited the activation of NF-κB and the DNA binding activity by TNFα proved by EMSA in these two AML cell lines. Moreover, in vivo studies showed that treatment with oroxylin A in combination with TNFα decreased AML cell population and prolonged survival in NOD/SCID mice with xenografts of primary AML cells. Overall, our results indicate that oroxylin A is able to inhibit the negative effects of TNFα for AML therapy, suggesting that combination of oroxylin A and TNFα have the potential to delay growth or eliminate the abnormal leukemic cells, thus representing a promising strategy for AML treatment.
Introduction
Acute myelogenous leukemia (AML), the most common acute leukemia, is a malignant blood cell disorder characterized by uncontrolled proliferation, differentiation disorder, apoptosis disruption and severely impairment of hematopoietic stem cells. AML cells proliferate in the bone marrow and other hematopoietic tissues with infiltration to other organs, inhibiting normal hematopoiesis (1) . In the past three decades, all-trans retinoic acid (ATRA) was successfully used for treatment of acute promyelocytic leukemia (APL), which is classified as AML M3 by the FAB system, suggesting a new and efficient therapy with less toxicity for cancer therapeutic strategy as 'differentiation therapy' (2) .
The proliferation and differentiation of leukemic cells are influenced by cell signaling pathways triggered by growth factors and cytokines. Tumor necrosis factor alpha (TNFα) released by activated macrophages is a relatively complicated cytokine, which is involved in proliferation, differentiation and many other cellular effects (3) (4) (5) . In the peripheral blood and bone marrow (BM) of most human leukemia patients, increased levels of TNFα are detected and are correlated to higher white blood cell counts (6) . NF-κB and TNFα are highly expressed in AML patients, and these two molecules are strongly correlated (7) . TNFα plays important roles in cell survival and death. However, it often fails to induce apoptosis in cancer cells because of its simultaneous activation of the NF-κB and/or the PI3K/AKT pathway (8, 9) .
RXRs are currently the most thoroughly studied nuclear receptor subfamily modulating target genes transcription by dimerizing with diverse nuclear receptors (10) . Retinoid X receptor-α (RXRα), a predominant isoform of RXRs, plays a role in many biological processes including carcinogenesis. In cancer cells, due to the limited proteolytic cleavage, RXRα also presented N-terminal truncated RXRα (tRXRα) proteins in the cytoplasm (11) . Studies have shown that TNFα can promote the interaction between tRXRα and P85α, the subunit of phosphatidylinositol 3-kinase (PI3-kinase), thereby activating the PI3K/AKT pathway (11) , but the aberrant PI3K/AKT signaling which could result in disturbance of cell differentiation or other aspects of tumor cells produces a negative effect on the treatment of AML (12) . Moreover, PI3K/AKT pathway negatively regulates differentiation through multiple mechanisms including the translation of c-Myc, translational inhibition of PDCD4, DAP5/P97 and important regulators of differentiation of AML cells (13) .
In addition, among all the biological functions of leukemic cells that are influenced by cell signaling pathways induced by TNFα, the NF-κB pathway has been studied to be constitutively active in most leukemic cells and involved in regulating the effects of various transcription factors responsible for proliferation of normal myeloid and leukemic cells (3) (4) (5) 14, 15) . Moreover, there is also evidence proving that the nuclear translocation of NF-κB regulates the expression of a number of genes including relA, survivin, bcl-2 and cyclin d1, which are involved in prolonged cell survival, antiapoptosis and cell cycle regulatory, accounting for its role in tumor promotion (16) . Besides, NF-κB was obviously increased in patients with leukemia, and the activation of NF-κB has been linked to cellular resistance of chemotherapeutic drugs and radiation treatment, suggesting that the inhibition of NF-κB pathway is a viable therapeutic strategy in the leukemia treatment (17, 18) .
In summary, the negative effect of TNFα on AML clinic therapy needs to be eliminated by identifying complementary agent, so the anti-AML potential of TNFα would be prominent. Oroxylin A is one of the major bioactive flavones from the root of Scutellaria baicalensis Georgi, a traditional Chinese herb. It has been confirmed that oroxylin A possesses a broad spectrum of pharmacological functions, including anti-inflammation, anticancer, neuroprotective and so on (19) (20) (21) . Oroxylin A has a high selectivity between normal cells and cancer cells (22) . As a natural product, its low toxicity ensures the safety and feasibility of combined use of drugs. We have previously demonstrated that oroxylin A has the capacity of decreasing tRXRα expression on AML cell lines including NB4, U937 and HL-60 (23) . Thus, we explored the differentiation induction and growth inhibition effects of the combination of oroxylin A and TNFα on those cell lines including ATRA-sensitive cells such as NB4 cell and some ATRA-resistant cells including U937-MDR and HL-60-resistant (24) . Moreover, we also examined the efficacy of the combined treatment on the ATRA-sensitive primary AML cells and ATRAresistant primary AML cells, searching for a novel strategy of treatment for the insensitive cells.
Materials and methods

Reagents and antibodies
Oroxylin A was isolated and purified from Scutellariae radix according to the established methods with slight modifications (25) . Oroxylin A used in all experiments was 99% or higher purity unless otherwise indicated. Oroxylin A was dissolved at a concentration of 0.5 M in dimethyl sulfoxide (DMSO) and stored at −20°C. The final DMSO concentration did not exceed 0.01% in the study. The control groups were treated with the highest concentration of DMSO in the corresponding experiments.
ATRA purchased from Sigma-Aldrich (St. Louis, MO) was dissolved to 0.1 M as a stock solution in DMSO stored at −20°C. All drugs in stock solutions were diluted with culture medium to final concentrations indicated in each assay.
For in vitro experiments, recombinant human TNFα was obtained from Prospec-Tany TechnoGene Ltd. (ProSpec, Israel). For in vivo analyses, TNFα (500 000 IU/ml) was purchased from Shanghai weike biopharmaceutical Co., Ltd (Shanghai, China), and mice were injected intravenously (i.v.) with or without TNFα (150 000 IU/kg).
Giemsa stain, nitroblue tetrazolium (NBT), phorbol 12-myristate 13-acetate (PMA) and 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO). A nuclear/cytosol fractionation kit (KeyGEN, Nanjing, China) was used according to the manufacturer's directions.
Phycoerythrin anti-human CD11b and fluorescein isothiocyanate (FITC) anti-human CD14 antibodies were obtained from Miltenyi Biotec (Teterow, Germany). Bovine serum albumin (BSA) was purchased from Roche (Mannheim, Germany). Antibodies for IκBα, NF-κB, RXRα and β-actin were obtained from Santa Cruz Biotechnology (1:500; Santa Cruz, CA). Antibodies for IKKα, p-IKKα and lamin A were obtained from Bioworld Technology Company Ltd. (1:800; Dublin, OH). Antibodies for p-AKT, AKT, PI3 kinase p85 and p-IκBα were obtained from Cell Signaling Technology, Inc. (1:1000; Beverly, MA). IRDyeTM 800-conjugated secondary antibodies were purchased from (Rockland Inc., Philadelphia, PA).
Cell cultures
Human NB4 cell line was purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology. Human U937-MDR and HL-60-resistant cells were provided by Professor Robert E. Gallagher, Department of Medicine, Albert Einstein College of Medicine. Human U937-MDR and HL-60-resistant cells were not authenticated in our laboratory, but were regularly tested to ensure they were mycoplasma-free (PlasmoTest™, InvivoGen, CA 
MTT assay
Cells were seeded into 96-well plates (Corning, New York, NY) at, respectively, indicated density in 100 μl fresh RPMI-1640 medium and then treated with oroxylin A (20 μM) or/and TNFα for 96 h, the combination group was pretreated with 20 μM oroxylin A for 24 h and then treated with TNFα at different concentrations for 96 h. Each group consisted of five parallel wells. Subsequently, 20 μl/well of MTT dye (5 mg/ml) was added, and then the plates were incubated for another 4 h at 37°C in a 5% CO 2 atmosphere. Then the precipitation of formazan crystals was collected by centrifugation at 4000 rpm/15 min. The supernatants were removed and DMSO (100 μl) was added to dissolve the precipitation. Subsequently, the plates were shaked for 2 min, and then absorbance was read at 570 nm on an automated microtiter plate reader (EL800, BIO-TEK Instruments Inc.). The concentration that caused 50 % inhibition of cell viabilities (IC50) values was calculated by GraphPad Software. All assays were performed in triplicate.
NBT reduction assay
The three cell lines were pretreated with or without oroxylin A for 24 h, and then treated with or without TNFα at indicated concentrations for 96 h. Cells were harvested and incubated with 200 μl supersaturated NBT solution containing 100 μg/ml PMA. After the cells were incubated at 37°C for 0.5 h, NBT positive cells containing blue deposit inside during 250 cells were calculated. The NBT positive ratio % was calculated by the following formula:
NBT positive ratio NBT positive cells counts 250 100 % % =÷
Giemsa staining
Cells pretreated with or without oroxylin A for 24 h, and then treated with or without TNFα at indicated concentrations for 96 h. Cells were harvested at 1000 rpm and collected on the slides, air-dried and fixed in methanol for 10 min at room temperature, and stained with Giemsa stain for 2 min. Then cells were observed under a light microscope (IX51; Olympus, Tokyo, Japan) and images were captured by DP2-BSW software (Olympus).
Cell-surface differentiation antigen expression analysis
Two cell-surface antigens CD11b and CD14 were measured by FACS Calibur flow cytometry (Becton-Dickinson, San Jose, CA) with a direct immunofluorescence analysis method. CD11b was used as a marker of granulocytic and monocytic differentiation while CD14 as monocytic differentiation. ATRA could induce granulocytic differentiation of leukemia cells. According to that character, we used ATRA as granulocytic positive controls. Briefly, cells were collected, blocked with 0.5% BSA, washed, and incubated with monoclonal mouse antihuman phycoerythrin-labeled anti-CD11b and FITC-labeled anti-CD14 for 45 min at 37°C. Fluorescence intensity was analyzed by flow cytometry. Data were based on examination of 10 000 cells/sample selected randomly from 5 × 10 5 cells.
Western blot analysis
Cells were collected, washed with ice-cold phosphate-buffered saline (PBS) and lysed with ice-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 3% nonidet P-40, 1 mM ethylenediaminetetraacetic acid and protease inhibitor phenylmethanesulfonyl fluoride (PMSF, NaF, leupeptin and dithiothreitol) on ice for 45 min. Cell lysates were centrifuged at 12 000 rpm (5430R; Eppendorf, Hamburg, Germany) for 30 min at 4°C and protein in the supernatant was quantified by BCA protein assay kit with a Varioskan multimode microplate spectrofluorometer and spectrophotometer (Thermo, Waltham, MA). Protein extracts were equally loaded on 10% SDS-polyacrylamide gel and electrophoretically transferred to nitrocellulose membranes (BiTrace NT, PallCor). The membranes were blocked with 1% BSA in PBS at 37°C for 1 h and incubated with primary antibody diluted at the indicated ratio in PBST (PBS and 0.1% Tween-20) at 37°C for 1.5 h and then 4°C overnight. The membranes were washed with PBST for three times for 0.5 h, and then were incubated with IRDye™800-conjugated secondary antibody for 55 min at 37°C. After washing the membranes with PBST for three times and then PBS for three times, each time for 10 min, detection was performed by the Odyssey Infrared Imaging System (Li-COR; Lincoln, NE) and blot band intensity was quantified by Odyssey software. All blots were stripped and reprobed with polyclonal anti-β-actin antibody to ascertain equal loading of protein. Cytosolic and nucleus proteins were prepared using a nuclear-cytosol extraction kit (Keygen, Nanjing, China) to assess distribution of NF-κB.
Coimmunoprecipitation assay
Cells were pretreated with or without oroxylin A for 24 h, and then treated with or without TNFα for 8 h in HL-60-resistant, and 0.5 h in NB4 cells. Next, cell lysate was incubated with RXRα antibody and 20 μl protein A/Gconjugated beads (Santa Cruz) at 4°C overnight. After three washes with PBS buffer, samples were collected and re-suspended in 20 μl SDS-sample buffer (0.5 M Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 5% 2-mercaptoethanol and 4‰ bromophenol blue) and boiled for 10 min. Then the samples were subjected to western blot with anti-RXRα and anti-p85α antibodies, followed by IRDyeTM 800-conjugated secondary antibody to assess level of RXRα and p85α for control.
Electrophoretic mobility shift assay (EMSA)
After pretreatment with oroxylin A for 24 h, and then co-treated with or without TNFα at indicated concentrations for 8 h in HL-60-resistant cells, and 0.5 h in NB4 cells, the nuclear protein was extracted using Nuclear and Cytoplasmic Protein Extraction Kit according to the manufacturer's protocol. EMSA was performed with a non-radioactive (biotin label) gel shift assay according to the manufacturer's protocol (Beyotime Institute of Biotechnology, Haimen, China). EMSA reactions were prepared by adding the following components: (1) 8 μg of nuclear extract protein from NB4 and HL-60-resistant cells; (2) 20 μl binding buffer; (3) 1 μl of biotin-labeled oligonucleotide probe (0.2 μM): NF-κB (5′-AGT TGA GGG GAC TTT CCC AGG C-3′, 3′-TCA ACT CCC CTG AAA GGG TCC G-5′) consensus oligonucleotide probe was end labeled with biotin with terminal deoxynucleotidyl transferase; (4) wild-type unlabeled NF-κB sequence; (5) mutated unlabeled NF-κB sequence: NF-κB (5′-AGT TGA GGC GAC TTT CCC AGG C-3′, 3′-TCA ACT CCC CTG AAA GGG TCC G-5′) and (6) antibodies of NF-κB. The mixture was incubated for 25 min at room temperature. Following the addition of 5 μl of sample buffer, the DNA-protein complexes were loaded on a 6% non-denaturing polyacrylamide gel in a 0.5× tris-borate-ethylenediaminetetraacetic acid buffer at 380 mA for 1 h and the transferred to positively charged nitrocellulose membrane and cross-linked in a Stratagene cross-linker. Finally, the gel shifts were visualized with Bio-Rad Infrared system by chemiluminescence using Chemiluminescent EMSA Kit (Beyotime, Nanjing, China).
RXRα siRNA transfection
RXRα siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and transfection was performed using Lipofectamine 2000TM reagent (Invitrogen, San Diego, CA) according to the manufacturer's instructions provided by the vendor (22) . The cells were then treated with oroxylin A or TNFα and harvested for western blots.
Immunofluorescence
The BM slides were permeabilized in 0.2% (v/v) Triton X-100 for 20 min and blocked with BSA buffer (PBS containing 3% BSA) for 1 h at room temperature. Then the BM slides were incubated with huCD45-FITC antibody (1:10) at 37°C for 1 h. Then slides were washed and counterstained with DAPI working solution (100 μg/ml) for 20 min at room temperature. The slides were covered by coverslips and immersed in a mounting medium. The images were captured with a confocal microscope at 1000× magnification (FV1000; Olympus, Tokyo, Japan).
Histological analysis
To characterize the histological alterations, the major organs from NOD/ SCID mice in each experimental group were immersed in 10% formaldehyde (pH 7.4) fixative for 24 h, embedded in paraffin, cut into sections 4 mm thick and stained with hematoxylin and eosin (H&E) using standard histological techniques.
Statistical analysis
All results were expressed as mean ± standard error of the mean (SEM). The data shown were obtained from triplicate independent parallel experiments. Statistical analyses of multiple-group comparisons were performed by one-way analysis of variance (ANOVA) followed by the Bonferroni post-test. Comparisons between two groups were analyzed using two-tailed Student t tests. The significance of differences is indicated as *P < 0.05, **P < 0.01.
Results
Oroxylin A inhibits TNFα-induced AKT activation correlated with downregulation of tRXRα expression
Aberrant PI3K/AKT signaling is frequently activated and associated with drug resistance and inhibition of differentiation of AML (26, 27) . Thus, we investigated whether TNFα-induced AKT activation was down-regulated by oroxylin A through modulation of tRXRα in NB4 and HL-60-resistant cells. To ascertain the valid time points of oroxylin A and TNFα treatments, we first examined the TNFα-triggered AKT phosphorylation level in NB4 and HL-60-resistant cells. As shown in Figure 1A and B, AKT activation reached a peak at 8 h after TNFα (20 ng/ml) treatment in HL-60-resistant cells, and 0.5 h in NB4 cells. Next, we examined the tRXRα expression level in the presence of oroxylin A for 0, 12, 24, 48, 72 and 96 h in NB4 and HL-60-resistant cells. The expression of tRXRα was inhibited by oroxylin A starting at 12 h and reached a low level at 24 h time point in these two cell lines ( Figure 1C and D) . In Figure 1E and F, NB4 and HL-60-resistant cells were pretreated with or without oroxylin A for 24 h, and then treated with TNFα at indicated time points, oroxylin A could suppress TNFα-induced AKT activation, which was correlated with decreased tRXRα expression.
Effects of combination of oroxylin A and TNFα on cell growth and differentiation in AML cell lines and primary AML cells
To further examine the influence of oroxylin A-induced PI3K/ AKT signaling inactivation on cell growth and differentiation, AML cell lines including NB4, U937-MDR and HL-60-resistant cells were pretreated with or without 20 μM oroxylin A for 24 h, or/and then incubated within indicated concentrations of TNFα or ATRA. As shown in Figure 2A , the viability of NB4, U937-MDR and HL-60-resistant cells were markedly reduced in combination groups compared with TNFα groups. Data revealed that in combination with TNFα (20 ng/ml) and oroxylin A (20 μM) could significantly increase the inhibitory ratio (60.3 ± 4.6%) in NB4 cells, (54.3 ± 5.2%) in U937-MDR cells and (62.9 ± 4.1%) in HL-60-resistant cells (Figure 2A) . Additionally, similar results were also observed in primary AML cells, as the combination of TNFα and oroxylin A could significantly increase the inhibitory ratio (50.5 ± 3.1%) in ATRA-sensitive primary AML cells ( Figure 3A) . Notably, results of MTT assay showed that the combination of TNFα and oroxylin A could also significantly increase the inhibitory effect on cell growth compared with the single treatment groups in ATRAresistant primary AML cells ( Figure 3E) . Moreover, the combination of oroxylin A and TNFα has no significant difference on the viability of normal human PBMC (Supplementary Figure 1, available at Carcinogenesis Online). Trypan blue exclusion assay also confirmed the inhibitory effect of TNFα/oroxylin A combination on cell proliferation compared with single-treatment groups at 96 h ( Figure 2B ). The fluorescence-activated cell sorting (FACS) Annexin V/PI double staining assay was used to examine cell apoptosis. Supplementary Figure 2 , available at Carcinogenesis Online, showed no obvious apoptotic effect after treatment of TNFα (10 ng/ml, 20 ng/ml) alone or combination with oroxylin A (20 μM) or with ATRA (1 μM) alone. Moreover, in view of effects on cell differentiation, we examined the NBT-reduction activity of AML cells to determine the differentiation degree. Results suggested that cells treated with combination of TNFα (20 ng/ml) and oroxylin A (20 μM) for 96 h showed an apparently higher positive rate of NBT-reduction activity in HL-60-resistant cells than either TNFα or oroxylin A alone ( Figure 2C ). We further investigated the differentiation effects by analyzing the expression of markers of myeloid differentiation (CD11b) and monocytic differentiation (CD14). In Figure 2D , data revealed that after incubation with TNFα and oroxylin A, the expression of CD11b on NB4 cells increased (31.2 ± 3.5%) while CD14 increased slightly (9.7 ± 1.1%). In U937-MDR cells, the percentage of CD11b-positive cells (17.4 ± 2.0%) increased as well as CD14 (26.2 ± 2.7%). In HL-60-resistant cells, TNFα and oroxylin A could increase the population of CD11b-positive (45.4 ± 5.3%) and CD14-positive (5.4 ± 0.6%) cells. It's worth mentioning that ATRA could significantly increase CD11b expression in NB4 cells (83.4 ± 9.0%) and U937-MDR (48.7 ± 5.1%), but not in HL-60-resistant cells (14.3 ± 1.6%), which is much lower than in the combination group. However, as shown in Figure 3B and C, ATRA could increase CD11b expression in primary AML cells (26.2 ± 1.1%). Additionally, combination of TNFα and oroxylin A could significantly increase the CD11b-positive (16.8 ± 1.3%) and CD14-positive (35.5 ± 1.7%) proportions in ATRA-sensitive primary AML cells. In addition, we further detected the differentiation induction effects of TNFα/oroxylin A co-treatment in ATRA-resistant primary AML cells by flow cytometry using a FACSCalibur flow cytometer. Data revealed that the expression of CD11b and CD14 in ATRA-resistant primary AML cells were also markedly increased ( Figure 3F and G) .
To further confirm the differentiation induction effect, cells were treated with TNFα (10 ng/ml, 20 ng/ml) and/or oroxylin A (20 μM) for 96 h and then stained with Giemsa stain to examine their morphology change. Compared with the TNFα-treated groups, NB4 and HL-60-resistant cells in the combination group were characterized as granulocytic features of cell differentiation, such as a round or oval nucleus peripherally located, anomalous cytoplasmic contours and grayish cytoplasm (28, 29) , while combination of oroxylin A and TNFα-treated U937-MDR cells showed morphological features as a decreased nuclear/ cytoplasmic ratio, ruffled membranes, and a larger cell size ( Figure 2E) (30,31) . The results indicated that combination of TNFα and oroxylin A induced granulocytic differentiation of NB4 and HL-60-resistant cells and monocytic differentiation of U937-MDR cells. Moreover, combination of oroxylin A and TNFα-treated primary AML cells also showed a marked morphology change of round or oval nucleus peripherally located, anomalous cytoplasmic contours, and grayish cytoplasm ( Figure 3D ). These results suggest that the combination of oroxylin A and TNFα could inhibit the growth and enhance differentiation of AML cell lines and primary AML cells.
Oroxylin A enhances TNFα-induced differentiation efficiency involving the regulation on tRXRα
tRXRα played a role in TNFα-induced AKT activation via interaction between tRXRα and p85α (11) . In Figure 4A -F, Results demonstrated that TNFα-increased the conjugation of tRXRα and p85α, Expression levels of AKT, p-AKT and tRXRα were analyzed by western blot using indicated antibodies. β-actin was used as a loading control. Each protein band was derived from different gels. Bars displayed are the relative ratios of phosphorylated AKT/total AKT and tRXRα/β-actin (mean ± SEM, n = 3, *P < 0.05, **P < 0.01 versus control). which was decreased by oroxylin A via inhibiting expression of tRXRα in NB4 and HL-60-resistant cells, while the protein interaction between tRXRα and p85α wasn't affected by oroxylin A. To investigate whether the differentiation-promoting effect of combination of oroxylin A and TNFα is dependent on tRXRα expression, NB4 and HL-60-resistant cells were transfected with RXRα siRNA and the efficacy of transfection was monitored by using Western blot ( Figure 4G ). Silencing of tRXRα expression significantly decreased TNFα-induced AKT activation. The difference between p-AKT level of TNFα group and the combination group was not obvious ( Figure 4G ). Moreover, specific PI3K inhibitor LY294002, which inhibits activation of AKT, was used to testify the effect of the inactivated PI3K/AKT pathways on the expression of c-Myc, a downstream target of p-AKT. The results indicated that LY294002 markedly decrease the TNFα-induced activity of c-Myc ( Figure 4H) . Similarly, after silencing of RXRα, the TNFα-treated group and the combination group also had no significant difference in the expression of CD11b and CD14 differentiation surface antigens in NB4 and HL-60-resistant cells ( Figure 4I and J). Meanwhile, we used RXRα siRNA to assess if the AKT plays an important role in cell growth and results showed that silencing RXRα enhanced the cells growth inhibition to some degree in TNFα alone group. However, it also has significant difference between the TNFα-treated group and the combination group, suggesting other molecular mechanisms underlying the inhibitory effects observed in our study ( Figure 4K) . Results above raised the possibility that oroxylin A could inhibit TNFα-induced AKT activation through regulating tRXRα expression. Moreover, the results indicated that, in these two AML cell lines, tRXRα could bind to p85α in the presence of TNFα, thus leading to AKT activation, which could be suppressed by oroxylin A by down-regulating tRXRα.
Oroxylin A inhibited TNFα-induced activation of NF-κB pathway
TNFα has the ability of activating NF-κB pathway which regulates transcription factors responsible for proliferation of most leukemic cells (3) (4) (5) . In addition, we have confirmed that the combination of TNFα and oroxylin A could inhibit the proliferation of NB4 and HL-60-resistant cells (Figures 2A and 4K) . Whether oroxylin A affects the excessive activation of NF-κB by TNFα would be worth clarifying. In response to TNFα stimuli, IkB, the sequestering protein of NF-κB, is phosphorylated by the IκB kinase complex (IKK) and then rapidly degraded by the proteasome after their poly-ubiquitination, allowing NF-κB to translocate into the nucleus and activate its target gene (32) . Our results showed that oroxylin A inhibited TNFα-induced phosphorylation of IKKα and IκBα ( Figure 5A and B) in both cell lines. Also, the effect of TNFα on nuclear translocation of NF-κB was inhibited by oroxylin A (Figure 5C and D) . Besides, we also investigated the effects of DNA binding activity of NF-κB using EMSA assay in both leukemia cell lines. In Figure 5E and F, the binding of NF-κB to the promoter containing its DNA binding site was upregulated dramatically upon TNFα treatment, while less significantly in cells treated with both TNFα and oroxylin A. Moreover, as it is well documented that NF-κB is down-stream of PI3K/AKT pathway, RXRα siRNA and LY294002 were used to further assess if the AKT is required for TNFα-induced IKKα/NF-κB activation. Results showed that either RXRα silencing or LY294002 pretreatment could not inhibit TNFα-induced phosphorylation of IKKα in NB4 and HL-60-resistant cells. Besides, the differences of p-IKKα levels between the untransfected group and RXR siRNA or LY294002 pretreatment group were not obvious, suggesting that the regulation effect of AKT is weak in activation of IKKα/NF-κB signal pathway induced by TNFα ( Figure 5G and H) . In conclusion, the reversion of NF-κB activation by oroxylin A might compensate for the disadvantage in AML therapy.
Effects of oroxylin A/TNFα combination on primary AML cells-bearing NOD/SCID mice
To further investigate the advantage of the combination of TNFα and oroxylin A in vivo, we examined the survival of primary AML cells-bearing NOD/SCID mice. The results showed that the combination of oroxylin A and TNFα significantly prolonged survival compared with the control group ( Figure 6A , log-rank P value＜0.01). The median survival time was 12.2 ± 1.2 days in the control group and 38.1 ± 2.3 days in the combination treatment group. In Figure 6B , immunofluorescence for CD45, a surface marker of human primary AML cells, revealed that engrafted AML cells had located and proliferated in BM section IKKα, and phosphorylated IκBα/total IκBα (mean ± SEM, n = 3, *P < 0.05, **P < 0.01 versus control). (C, D) Cytoplasmic/membrane and nuclear fractions of the cells were analyzed by western blot for the NF-κB protein, with β-actin and LaminA as cytoplasmic and nuclear loading controls, respectively. Each protein band was derived from different gels. Bars displayed are the relative ratios of NF-κB/LaminA, NF-κB/β-actin, in both cell lines (mean ± SEM, n = 3, *P < 0.05, **P < 0.01 versus control). (E, F) EMSA assay to detect NF-κB binding to its consensus site is shown. The nuclear extracts were prepared and assayed for NF-κB DNA binding activity using a labeled probe containing the area of NF-κB binding site. To determine the composition of the DNA-binding complex, the anti-NF-κB antibody was used for super-shift experiments.
Bars displayed are the relative ratios of supershift binds/free oligos (mean ± SEM, n = 3, *P < 0.05, **P < 0.01 versus control). of AML-bearing mice. Furthermore, in the single treatment groups, CD45
+ cells slightly and sporadically distributed in BM compared with the control, while the combination treatment group showed almost no infiltration of CD45 + cells, suggesting better anti-AML efficiency in vivo. In addition, the histological alterations of major organs from the AML animal models were detected using H&E staining. In primary AML cells-bearing NOD/SCID mice, the combination of oroxylin A and TNFα has no pathological abnormalities compared with the control group. Meanwhile, the pathological changes of tissues were alleviated to a certain extent, suggesting the safety and feasibility of combined use of oroxylin A and TNFα. (Supplementary Figure 3 and Table 1 , available at Carcinogenesis Online).
Discussion
In our study on antileukemia therapy of TNFα combined with oroxylin A, we demonstrate that TNFα has slight growth inhibition and differentiation induction effects on AML cell lines and primary AML cells through NBT reduction, Giemsa staining and cell surface antigen flow cytometry assays, but the growth inhibition and terminal differentiation function caused by TNFα was markedly increased when combined with oroxylin A at an apoptotic insensitive dose (Figures 2 and 3, Supplementary  Figure 2 , available at Carcinogenesis Online).
The study revealed that oroxylin A and TNFα together induced granulocytic differentiation of NB4 and HL-60-resistant cells and monocytic differentiation of U937-MDR cells. However, according to our previous studies, oroxylin A (40 μM) has the ability to induce monocytic differentiation of HL-60 cell lines (23), which was not consistent with our results of combination of oroxylin A (20 μM) and TNFα. We conjectured that in the combination group the differentiation lineage was different mainly because TNFα played a dominant role in determining the differentiation direction. NB4 cells have low sensitivity to oroxylin A (40 μM) in differentiation induction (23) , while the combination treatment with TNFα could enhance the differentiation effect on NB4 cells with a relative lower dose of oroxylin A (20 μM), which might be possibly due to decreasing interaction between tRXRα and p85α according to this study. On the other hand, the RA-resistant HL-60 cells had a low response to ATRA (Figure 2 ) in inducing differentiation, yet the differentiation effect could be increased by combination of oroxylin A and TNFα, suggesting that oroxylin A/TNFα treatment might have the ability of being a new candidate of differentiation therapy for ATRA-resistant AML patients. Moreover, ATRA-sensitive and ATRA-resistant primary AML cells treated with combination oroxylin A (20 μM) and TNFα (20 ng/ml) also showed marked growth inhibition and myeloid differentiation effects (Figure 3) , suggesting the feasibility of combination strategy in AML therapy. PI3K/AKT pathway, which plays an important role in cell proliferation, invasion, and cell differentiation, has been reported to block leukemic cell differentiation through multiple mechanisms such as the upregulation of c-Myc and translational inhibition of PDCD4 and DAP5/P97, which are the important regulators of both granulocytic and monocytic differentiation of AML cells (13, 33, 34) . In our study, we have further ascertained that TNFα could promote the interaction between PI3K subunit p85α and tRXRα, thereby activating AKT expression without modification of PI3K protein level, which had been confirmed by transfecting siRNA of RXRα. On the contrary, the activation state of AKT was decreased observably, in the presence of TNFα-oroxylin A combination, through down-regulating tRXRα.
The NF-κB pathway, including IKKα, IκBα and NF-κB DNA binding were activated by TNFα, which could be reversed by combination of TNFα and oroxylin A ( Figure 5 ). In conclusion, the activation of AKT and NF-κB pathways induced by TNFα is unconducive for both growth inhibition and differentiation of leukemia cells. Nevertheless, oroxylin A might overcome the drawback of overly activation of AKT and NF-κB pathways, leading to more significant growth inhibition and higher differentiation efficacy than the treatment of TNFα alone. On the whole, TNFα has complicated effects on numerous pathways such as JNK, PKC (35, 36) , AKT and NF-κB pathways as mentioned above. Therefore, we speculated the negative effect of AKT on inducing leukemic cells to differentiation and the adverse effect of NF-κB pathways on inhibiting leukemic cells proliferation might account for the relatively weak growth inhibition and terminal differentiation effect induced by TNFα in leukemia cells (Supplementary Figure 4 , available at Carcinogenesis Online). Among all the above pathways, oroxylin A might have the ability of counteracting the negative effect of AKT and NF-κB signaling pathway or some others unknown mechanism to trigger a higher growth inhibition and leukemic cell differentiation, rather than TNFα alone. Moreover, oroxylin A, a natural product, has low toxicity and ensures the safety and feasibility of combined use of drugs. The results of histological alterations of major organs from the experimental animal models also confirmed that the combination of oroxylin A and TNFα showed no pathological abnormalities in vivo (Supplementary Figure 3 and Table 1 , available at Carcinogenesis Online).
The role of TNFα is as important cytokine is proved in many cancer patients and has been successfully recombined in vitro and applied for tumor therapy (37) (38) (39) (40) . However, it still remains unknown why the AML patients with high TNFα expression are more likely to have poor prognosis. Plenty of investigations have confirmed that TNFα could induce apoptosis and differentiation of AML cells in vitro (41) (42) (43) (44) , but has not yet been applied successfully in clinical AML therapy. Further studies have shown that TNFα activates proliferation/survival signals such as NF-κB, the PI3K/AKT pathway and/or RIP1/RIP3/MLKL signaling (8, 9, 11, 45, 46) , which impairs its antileukemic effects. Many research groups have successfully increased the anti-AML activity of TNFα by interfering with the activation of adverse pathways such as RIP1/RIP3 pathway (41, 43, 46) , but no effective drug combination strategy has yet been reported. To that end, our current studies indicated the potential of oroxylin A/TNFα combination to inhibit the growth of abnormal leukemic cells, which may benefit certain AML patients without deleterious side-effects.
TNFα can induce differentiation of fresh blast cells from AML patients in vitro (47) . Actually, AML is comprised of 11 different disease entities based on the genetic diversity (48) . Here, primary AML cells only involve a small subset of these various AML subtypes, corresponding to one of the cell lines. The problem about complexity and contradiction of TNFα needs to be resolved by combination therapy in AML. In view of the above conclusions, the combinational administration of TNFα and oroxylin A might have the potential to become a new strategy for the treatment of AML.
Conclusions
In summary, as shown in Supplementary Figure 4 , available at Carcinogenesis Online, our results demonstrate that, increasing levels of TNFα in human AML cells induces PI3K/AKT activation via promoting PI3K subunit p85α binding to N-terminal truncated nuclear receptor RXRα (tRXRα) proteins, thus leading to the inhibition of AML cell differentiation. Meanwhile, TNFα initiates the activation of NF-κB pathway. Activated NF-κB is recruited to the promoter containing its DNA binding site, leading to an increase in AML cell growth. However, oroxylin A can inhibit activation of AKT induced by TNFα via down-regulating tRXRα expression. In addition, oroxylin A also can also inhibit NF-κB signaling pathway and enhance TNFα-induced growth inhibition. Oroxylin A sensitizes leukemia cells to TNFα and enhances the anti-AML effects of TNFα. 
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